{"id":"vancomycin-or-equivalent","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Hypersensitivity reactions"},{"rate":"<1%","effect":"Anaphylaxis"}]},"_chembl":{"chemblId":"CHEMBL262777","moleculeType":"Small molecule","molecularWeight":"1449.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This prevents the incorporation of these precursors into the bacterial cell wall, ultimately leading to cell lysis and death. Vancomycin is a glycopeptide antibiotic that is effective against a wide range of Gram-positive pathogens.","oneSentence":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:30.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)"},{"name":"Treatment of severe or life-threatening infections caused by susceptible Gram-positive bacteria"}]},"trialDetails":[{"nctId":"NCT06126731","phase":"PHASE1, PHASE2","title":"Combination Study of Antibiotics With Enzalutamide (PROMIZE)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2023-11-02","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":39},{"nctId":"NCT03200093","phase":"PHASE4","title":"Oral Vancomycin for Preventing Clostridium Difficile Recurrence","status":"TERMINATED","sponsor":"Rochester General Hospital","startDate":"2017-06-08","conditions":"Clostridium Difficile Infection","enrollment":65},{"nctId":"NCT02426918","phase":"PHASE2","title":"Study of Debio 1450 for Bacterial Skin Infections","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2015-05","conditions":"Bacterial Infections","enrollment":330},{"nctId":"NCT01922011","phase":"PHASE3","title":"Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2013-09-13","conditions":"Acute Hematogenous Osteomyelitis","enrollment":149},{"nctId":"NCT01619982","phase":"PHASE4","title":"Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-02","conditions":"Congenital Heart Diseases, Aortic Valve Disorder","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":317,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vancomycin (or equivalent)","genericName":"Vancomycin (or equivalent)","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors. Used for Treatment of acute bacterial skin and skin structure infections (ABSSSI), Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), Treatment of severe or life-threatening infections caused by susceptible Gram-positive bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}